← Back to home

Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at cervical site

Clinical trials for Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at cervical site explained in plain language.

Never miss a new study

Get alerted when new Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at cervical site trials appear

Sign up with your email to follow new studies for Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at cervical site, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1

HPV vaccine may stop precancerous lesions from returning

Prevention Not yet recruiting

This study tests whether the HPV vaccine can prevent the return of high-grade squamous intraepithelial lesions (HSIL) in people who have already been treated for them. About 984 adults aged 18–55 with HPV-related HSIL of the cervix, vulva, vagina, penis, or anus will receive eith…

Matched conditions: PATIENTS WITH PRIMARY HPV HIGH-GRADE SQUAMOUS INTRA-EPITHELIAL LESIONS (HSIL) AT CERVICAL SITE

Phase 3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Prevention

Last updated Jun 27, 2026 09:08 UTC

Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at cervical site

Get alerted when new Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at cervical site trials appear

HPV vaccine may stop precancerous lesions from returning